Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 3
2002 2
2003 1
2004 3
2005 3
2006 3
2007 7
2008 7
2009 6
2010 5
2011 3
2012 4
2013 8
2014 2
2015 2
2016 2
2017 5
2018 2
2019 4
2020 1
2021 3
2022 4
2023 2
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Results by year

Filters applied: . Clear all
Page 1
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, Perrot A, Cavo M, Belotti A, Broijl A, Gay F, Mina R, Nijhof IS, van de Donk NWCJ, Katodritou E, Schjesvold F, Sureda Balari A, Rosiñol L, Delforge M, Roeloffzen W, Silzle T, Vangsted A, Einsele H, Spencer A, Hajek R, Jurczyszyn A, Lonergan S, Ahmadi T, Liu Y, Wang J, Vieyra D, van Brummelen EMJ, Vanquickelberghe V, Sitthi-Amorn A, de Boer CJ, Carson R, Rodriguez-Otero P, Bladé J, Moreau P; PERSEUS Trial Investigators. Sonneveld P, et al. Among authors: mangiacavalli s. N Engl J Med. 2024 Jan 25;390(4):301-313. doi: 10.1056/NEJMoa2312054. Epub 2023 Dec 12. N Engl J Med. 2024. PMID: 38084760 Clinical Trial.
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M; OPTIMISMM trial investigators. Richardson PG, et al. Lancet Oncol. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13. Lancet Oncol. 2019. PMID: 31097405 Clinical Trial.
Non-Secretory Myeloma: Ready for a new Definition?
Corso A, Mangiacavalli S. Corso A, et al. Among authors: mangiacavalli s. Mediterr J Hematol Infect Dis. 2017 Aug 18;9(1):e2017053. doi: 10.4084/MJHID.2017.053. eCollection 2017. Mediterr J Hematol Infect Dis. 2017. PMID: 28894562 Free PMC article. Review.
Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis.
Basset M, Defrancesco I, Milani P, Nuvolone M, Rattotti S, Foli A, Mangiacavalli S, Varettoni M, Benvenuti P, Cartia CS, Paulli M, Merlini G, Arcaini L, Palladini G. Basset M, et al. Among authors: mangiacavalli s. Blood. 2020 Jan 23;135(4):293-296. doi: 10.1182/blood.2019002762. Blood. 2020. PMID: 31714952 Free article. No abstract available.
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials.
Gentile M, Vigna E, Palmieri S, Galli M, Derudas D, Mina R, Della Pepa R, Zambello R, Martino EA, Bruzzese A, Mangiacavalli S, Zamagni E, Califano C, Musso M, Conticello C, Cerchione C, Mele G, Di Renzo N, Offidani M, Tarantini G, Casaluci GM, Rago A, Ria R, Uccello G, Barilà G, Palumbo G, Pompa A, Vincelli D, Brunori M, Accardi F, Amico V, Amendola A, Fontana R, Bongarzoni V, Rossini B, Cotzia E, Gozzetti A, Rizzi R, Sgherza N, Ferretti E, Bertuglia G, Nappi D, Petrucci MT, Di Raimondo F, Neri A, Morabito F, Musto P. Gentile M, et al. Among authors: mangiacavalli s. Haematologica. 2024 Jan 1;109(1):245-255. doi: 10.3324/haematol.2023.283251. Haematologica. 2024. PMID: 37439329 Free PMC article.
Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysis.
Mangiacavalli S, Cartia CS, Galli M, Pezzatti S, Belotti A, Fazio F, Mina R, Marcatti M, Cafro A, Zambello R, Paris L, Barilà G, Olivares C, Pompa A, Mazza R, Farina F, Soldarini M, Benvenuti P, Pagani G, Palumbo M, Masoni V, Ferretti VV, Klersy C, Arcaini L, Petrucci MT. Mangiacavalli S, et al. Haematologica. 2023 Mar 1;108(3):833-842. doi: 10.3324/haematol.2022.281342. Haematologica. 2023. PMID: 36200419 Free PMC article.
An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis.
Nevone A, Girelli M, Mangiacavalli S, Paiva B, Milani P, Cascino P, Piscitelli M, Speranzini V, Cartia CS, Benvenuti P, Goicoechea I, Fazio F, Basset M, Foli A, Nanci M, Mazzini G, Caminito S, Sesta MA, Casarini S, Rognoni P, Lavatelli F, Petrucci MT, Olimpieri PP, Ricagno S, Arcaini L, Merlini G, Palladini G, Nuvolone M. Nevone A, et al. Among authors: mangiacavalli s. Leukemia. 2022 Aug;36(8):2076-2085. doi: 10.1038/s41375-022-01599-w. Epub 2022 May 24. Leukemia. 2022. PMID: 35610346 Free article.
The advantages of switch to subcutaneous bortezomib in the real life.
Mangiacavalli S, Cocito F, Ferretti VV, Ganzetti M, Cartia CS, Corso A. Mangiacavalli S, et al. Leuk Lymphoma. 2018 Jun;59(6):1505-1507. doi: 10.1080/10428194.2017.1382695. Epub 2017 Oct 5. Leuk Lymphoma. 2018. PMID: 28980500 No abstract available.
Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms.
Varettoni M, Arcaini L, Zibellini S, Boveri E, Rattotti S, Riboni R, Corso A, Orlandi E, Bonfichi M, Gotti M, Pascutto C, Mangiacavalli S, Croci G, Fiaccadori V, Morello L, Guerrera ML, Paulli M, Cazzola M. Varettoni M, et al. Among authors: mangiacavalli s. Blood. 2013 Mar 28;121(13):2522-8. doi: 10.1182/blood-2012-09-457101. Epub 2013 Jan 25. Blood. 2013. PMID: 23355535 Free article.
69 results